EP3911350A4 - Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof - Google Patents

Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof Download PDF

Info

Publication number
EP3911350A4
EP3911350A4 EP20741089.5A EP20741089A EP3911350A4 EP 3911350 A4 EP3911350 A4 EP 3911350A4 EP 20741089 A EP20741089 A EP 20741089A EP 3911350 A4 EP3911350 A4 EP 3911350A4
Authority
EP
European Patent Office
Prior art keywords
fabricating
methods
pharmaceutical formulations
adrenocorticotropic hormone
based pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20741089.5A
Other languages
German (de)
French (fr)
Other versions
EP3911350A1 (en
Inventor
Dennis Elias Saadeh
Mark L. Baum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harrow IP LLC
Original Assignee
Harrow IP LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/250,711 external-priority patent/US11338018B2/en
Application filed by Harrow IP LLC filed Critical Harrow IP LLC
Publication of EP3911350A1 publication Critical patent/EP3911350A1/en
Publication of EP3911350A4 publication Critical patent/EP3911350A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP20741089.5A 2019-01-17 2020-01-14 Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof Withdrawn EP3911350A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/250,711 US11338018B2 (en) 2016-12-19 2019-01-17 Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof
PCT/US2020/013543 WO2020150262A1 (en) 2019-01-17 2020-01-14 Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof

Publications (2)

Publication Number Publication Date
EP3911350A1 EP3911350A1 (en) 2021-11-24
EP3911350A4 true EP3911350A4 (en) 2022-12-14

Family

ID=71613567

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20741089.5A Withdrawn EP3911350A4 (en) 2019-01-17 2020-01-14 Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof

Country Status (2)

Country Link
EP (1) EP3911350A4 (en)
WO (1) WO2020150262A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11338018B2 (en) 2016-12-19 2022-05-24 Harrow Ip, Llc Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130581A1 (en) * 2013-02-20 2014-08-28 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
US20180169191A1 (en) * 2016-12-19 2018-06-21 Eton Pharmaceuticals, Inc. Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
WO2008049011A2 (en) * 2006-10-18 2008-04-24 Research Development Foundation Alpha-msh therapies for treatment of autoimmune disease
EP2968475A2 (en) * 2013-03-14 2016-01-20 Questcor Pharmaceuticals, Inc. Acth for treatment of acute respiratory distress syndrome
GB201315335D0 (en) * 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014130581A1 (en) * 2013-02-20 2014-08-28 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
US20180169191A1 (en) * 2016-12-19 2018-06-21 Eton Pharmaceuticals, Inc. Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2020150262A1 *

Also Published As

Publication number Publication date
WO2020150262A1 (en) 2020-07-23
EP3911350A1 (en) 2021-11-24

Similar Documents

Publication Publication Date Title
EP3868367A4 (en) Micro-effervescent buccal tablet and preparation method thereof
EP4045480A4 (en) Pharmaceutical formulations
EP3351242A4 (en) Cannabinoid-containing oral pharmaceutical composition, method for preparing and using same
EP3737421A4 (en) Methods for antibody drug conjugation, purification, and formulation
EP3541385A4 (en) Pharmaceutical formulations
EP3725297A4 (en) Oral pharmaceutical composition containing pemetrexed and production method thereof
EP3554486A4 (en) Pharmaceutical formulations for treating glaucoma and methods for fabricating and using thereof
IL285674A (en) Pharmaceutical formulations
EP3452033A4 (en) Pharmaceutical ophthalmic compositions and methods for fabricating thereof
EP4041274A4 (en) Ws-635 uses thereof in medicine
EP3750537A4 (en) Pharmaceutical composition, excipient for the composition and use of the composition
EP3778588A4 (en) Quaternary lactam compound and pharmaceutical use thereof
EP3424521A4 (en) Pharmaceutical composition and manufacturing method thereof
EP3618810A4 (en) Train-like pharmaceutical configuration, apparatus for preparation and storage device thereof
EP3911350A4 (en) Adrenocorticotropic hormone-based pharmaceutical formulations and methods for fabricating and using thereof
EP4015001A4 (en) Oral pharmaceutical composition
EP3813842A4 (en) Pharmaceutical composition and preparation method thereof
EP3881841A4 (en) Pharmaceutical composition
EP3873437A4 (en) Aqueous pharmaceutical formulations
EP3792260A4 (en) Azabenzimidazole compounds and pharmaceutical
EP3381467A4 (en) Vaccine pharmaceutical composition for oral administration and method for manufacturing vaccine pharmaceutical composition for oral administration
EP3972607A4 (en) Pharmaceutical combination
EP3984549A4 (en) Medicinal composition
EP3949952A4 (en) Medicinal composition
EP3870149A4 (en) Decalin derivatives, a process for the preparation and pharmaceutical composition thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210729

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40063684

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0038000000

Ipc: A61K0009000000

A4 Supplementary search report drawn up and despatched

Effective date: 20221114

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/09 20060101ALI20221108BHEP

Ipc: C07K 14/695 20060101ALI20221108BHEP

Ipc: A61K 38/35 20060101ALI20221108BHEP

Ipc: A61K 38/22 20060101ALI20221108BHEP

Ipc: A61K 38/00 20060101ALI20221108BHEP

Ipc: A61K 47/38 20060101ALI20221108BHEP

Ipc: A61K 47/18 20170101ALI20221108BHEP

Ipc: A61K 9/50 20060101ALI20221108BHEP

Ipc: A61K 9/00 20060101AFI20221108BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20230613